609 related articles for article (PubMed ID: 23444223)
1. hTERT inhibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cells: a basis for new therapies.
Giunco S; Dolcetti R; Keppel S; Celeghin A; Indraccolo S; Dal Col J; Mastorci K; De Rossi A
Clin Cancer Res; 2013 Apr; 19(8):2036-47. PubMed ID: 23444223
[TBL] [Abstract][Full Text] [Related]
2. hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesis.
Terrin L; Dolcetti R; Corradini I; Indraccolo S; Dal Col J; Bertorelle R; Bonaldi L; Esposito G; De Rossi A
Int J Cancer; 2007 Aug; 121(3):576-87. PubMed ID: 17417773
[TBL] [Abstract][Full Text] [Related]
3. Cross talk between EBV and telomerase: the role of TERT and NOTCH2 in the switch of latent/lytic cycle of the virus.
Giunco S; Celeghin A; Gianesin K; Dolcetti R; Indraccolo S; De Rossi A
Cell Death Dis; 2015 May; 6(5):e1774. PubMed ID: 26018735
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
5. Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin.
Hsu CH; Hergenhahn M; Chuang SE; Yeh PY; Wu TC; Gao M; Cheng AL
Anticancer Res; 2002; 22(6C):4065-71. PubMed ID: 12553034
[TBL] [Abstract][Full Text] [Related]
6. Activators of the Epstein-Barr virus lytic program concomitantly induce apoptosis, but lytic gene expression protects from cell death.
Inman GJ; Binné UK; Parker GA; Farrell PJ; Allday MJ
J Virol; 2001 Mar; 75(5):2400-10. PubMed ID: 11160743
[TBL] [Abstract][Full Text] [Related]
7. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies.
Westphal EM; Blackstock W; Feng W; Israel B; Kenney SC
Cancer Res; 2000 Oct; 60(20):5781-8. PubMed ID: 11059774
[TBL] [Abstract][Full Text] [Related]
8. Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.
Celeghin A; Giunco S; Freguja R; Zangrossi M; Nalio S; Dolcetti R; De Rossi A
Cell Death Dis; 2016 Dec; 7(12):e2562. PubMed ID: 28032863
[TBL] [Abstract][Full Text] [Related]
9. TLR9 triggering in Burkitt's lymphoma cell lines suppresses the EBV BZLF1 transcription via histone modification.
Zauner L; Melroe GT; Sigrist JA; Rechsteiner MP; Dorner M; Arnold M; Berger C; Bernasconi M; Schaefer BW; Speck RF; Nadal D
Oncogene; 2010 Aug; 29(32):4588-98. PubMed ID: 20514021
[TBL] [Abstract][Full Text] [Related]
10. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
11. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
12. Short, discontinuous exposure to butyrate effectively sensitizes latently EBV-infected lymphoma cells to nucleoside analogue antiviral agents.
Ghosh SK; Forman LW; Akinsheye I; Perrine SP; Faller DV
Blood Cells Mol Dis; 2007; 38(1):57-65. PubMed ID: 17161633
[TBL] [Abstract][Full Text] [Related]
13. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
14. Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells.
Fagard R; Mouas H; Dusanter-Fourt I; Devillers C; Bissières P; Martin A; Lenoir G; VanTan H; Feuillard J; Raphaël M
Oncogene; 2002 Jul; 21(29):4473-80. PubMed ID: 12085225
[TBL] [Abstract][Full Text] [Related]
15. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
17. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
19. Aspirin induces lytic cytotoxicity in Epstein-Barr virus-positive cells.
Liu SF; Wang H; Li ZJ; Deng XY; Xiang H; Tao YG; Li W; Tang M; Cao Y
Eur J Pharmacol; 2008 Jul; 589(1-3):8-13. PubMed ID: 18571159
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
